Tech Company Financing Transactions
ImpriMed Funding Round
ImpriMed secured a $23 million Series A funding round on 12/19/2023. Investors included Byucksan, Han River Partners and Ignite Innovation Fund.
Transaction Overview
Company Name
Announced On
12/19/2023
Transaction Type
Venture Equity
Amount
$23,000,000
Round
Series A
Investors
Proceeds Purpose
The company intends to use the funds to expand its drug response prediction technology beyond veterinary medicine into human oncology, increase headcount, and broaden its business development and research and development pipeline.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
4030 Fabian Way
Palo Alto, CA 94303
USA
Palo Alto, CA 94303
USA
Phone
Undisclosed
Website
Email Address
Overview
ImpriMed develops a personalized drug testing service to look into drug responses of pet patient's live cancer cells before treatment. The company helps veterinary oncologists decide a final treatment regimen based on data-driven prediction of response success in each individual patient body and builds up a patient-derived database.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Sungwon Lim
Co-Founder
Mainak Chowdhury
Co-Founder
Jamin Koo
Co-Founder
David Kurtz
Co-Founder
Hye Lee
VP - Operations
Mary Ocnean
Browse more venture capital transactions:
Prev: 12/19/2023: Halcyon venture capital transaction
Next: 12/19/2023: Atavistik Bio venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on funding rounds that are announced publicly. VC investment data records reported here come from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs